세계의 임상 검사 서비스 시장 규모는 2024년 2,569억 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2033년에는 3,918억 달러에 달하고, 2025-2033년까지 4.80%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측했습니다. 현재 북미가 시장을 독점하고 있으며 2024년에는 39.2% 이상의 큰 시장 점유율을 차지하고 있습니다. 당뇨병 관리를 위한 혈당 검사, HbA1c 검사, 지질 프로파일 등의 진단 검사에 대한 수요 증가, 헬스케어 장벽을 줄이고 전체 검사량을 늘릴 수 있기 때문에 임상 검사 서비스에 액세스하기 위한 원격 의료에 대한 의존도 증가, 정밀의료 동향 증가와 임상 검사 서비스 시장 점유율에 긍정적인 요인이 되고 있습니다.
임상 검사 서비스 시장은 몇 가지 중요한 요인에 의해 견인되고 있습니다. 만성 질환과 전염병의 세계적인 증가로 조기 및 정확한 진단이 필요하며 실험실 검사에 대한 수요가 증가하고 있습니다. 자동화, 분자진단, AI 기반 도구 등의 기술 발전으로 검사의 정확성, 속도, 효율성이 향상되고 전체 서비스 제공이 강화됩니다. 건강 문제를 일으키기 쉬운 고령화 사회는 정기적이고 전문적인 검사의 필요성을 더욱 향상시키고 있습니다. 예방 건강 관리 및 건강 진단에 대한 의식 증가도 시장 확대에 기여합니다. 또한 맞춤형 의료 및 동반자 진단의 성장은 고급 검사 서비스에 대한 수요를 증가시키고 있습니다. 또한 정부의 이니셔티브, 헬스케어 접근성 개선, 의료보험 적용 확대도 현대 헬스케어에서 임상실의 역할 확대를 뒷받침하고 있습니다.
미국에서의 임상검사 서비스 시장의 성장은 암, 당뇨병, 심혈관장애 등 만성질환의 유병률 상승에 의해 촉진되어 진단검사에 대한 수요를 높이고 있습니다. 분자진단과 자동화를 포함한 검사 기술의 발전으로 검사 정확도와 납기가 향상되었습니다. 인구 고령화, 건강 의식 증진, 예방 의료의 중시는 일상적인 검사 서비스와 전문 검사 서비스의 필요성을 더욱 가속화하고 있습니다. 또한 보험 적용 범위 확대와 질병 조기 발견에 대한 정부의 지원도 시장 성장에 기여하고 있습니다. 예를 들어, 미국 검사 서비스 회사 Labcorp는 2024년 6월, 특히 임상시험 의사 거점에서 임상시험을 가속화하기 위한 중앙 실험실 솔루션 모음인 Labcorp Global Trial Connect를 발표했습니다. 이 디지털 및 데이터 솔루션은 임상시험의 효율화, 데이터 지연 최소화, 임상 책임 의사 시설의 워크플로우 간소화를 목표로 합니다. Labcorp Central Laboratory의 기존 고객도 이용 가능하며 임상시험 시작 가속화, 시험 진행 유지 및 시험 효율성 향상을 목표로 합니다.
임상 검사 서비스 시장 동향
당뇨병 유병률 상승
당뇨병 관리를 위한 HbA1c 검사, 혈당 검사, 지질 프로파일 등의 진단 검사에 대한 수요가 증가하고 있습니다. 이러한 검사는 당뇨병 진단, 혈당 모니터링, 관련 심혈관 위험 인자 평가에도 필수적입니다. 당뇨병을 효과적으로 관리하려면 정기적으로 혈당를 모니터링해야 합니다. 임상 실험실은 혈당 조절, 신장 기능, 지질 수준 및 기타 바이오 마커를 모니터링하는 데 도움이 되므로 매우 중요합니다. 당뇨병 망막증, 신증, 신경 장애 등의 합병증을 예방하기 위해 임상 실험실에서 스크리닝 검사를 실시했습니다. 이러한 스크리닝 검사는 당뇨병의 진행을 예방하기 위해 적시에 개입할 수 있습니다. 포인트 오브 케어 검사(POCT)는 신속한 검사가 가능하며 즉시 결과가 나오기 때문에 사람들에게 선호됩니다. 이 검사는 당뇨병 환자 모니터링에 효과적입니다. IDF Diabetes Atlas 웹사이트에 게재된 데이터에 따르면 2045년까지 약 7억 8,300만 명이 당뇨병을 앓을 것으로 예측됩니다.
정밀의료에 대한 수요 증가
IMARC Group의 보고서에 따르면 세계 정밀의료 시장은 2023년 752억 달러에 달했습니다. 바이오마커, 유전자 변이, 특정 분자 표적을 확인하는 정밀의료에는 유전자 검사, 유전체 시퀀싱 및 분자진단이 중요합니다. 임상 검사 서비스 시장 예측에 따르면, 이러한 검사는 임상 실험실에서 수행되며 질병 위험 예측, 개인의 유전적 특성에 따라 가장 효과적인 치료법 선택, 치료 정책 결정에 도움이 됩니다. 동반진단을 개발하고 시행하기 위해서는 임상 실험실이 매우 중요하며 시장 성장을 강화하고 있습니다. 동반자 진단은 특정 표적 치료의 성공률을 계산하기 위해 바이오 마커를 확인하는 데 사용되는 검사입니다. 이것을 알면 종양학, 감염 및 기타 치료 분야에서 치료 선택을 최적화할 수 있습니다. 개인에서 약물의 반응을 모니터링하기 위해 유전적 돌연변이를 분석하는 것이 매우 중요하며, 파마코유전체학는 이 분석에서 중요한 역할을 합니다. 임상 실험실은 약물의 효능, 필요한 양 및 잠재적인 부작용을 예측하기 위해 약리 유전체 검사를 제공합니다.
원격 의료 동향 증가
원격 의료는 원격지에 있어도 의사와 연결될 수 있기 때문에 현재 사람들에게 선호되고 있습니다. 또한 원격 의료 플랫폼을 통해 임상 검사 서비스에 액세스할 수 있어 건강 관리에 대한 장벽을 줄이고 전체 검사량을 늘릴 수 있습니다. 원격 의료를 통해 당뇨병과 같은 만성 질환의 원격 모니터링이 쉬워집니다. 임상 실험실은 이러한 질병의 지속적인 관리와 환자 결과를 개선하는 데 매우 중요합니다. 원격 의료 시장에서 사업을 전개하는 주요 기업은 고객 기반을 확대하기 위해 협력 및 제휴에 주력하고 있습니다. 예를 들어, 2023년 Zoom Video Communications, Inc.와 Oracle은 보다 빠르고 간편하며 효율적인 의료 서비스를 제공하기 위해 제휴를 확대했습니다. 재택 키트는 임상검사기관으로부터 배포되어, 재택에서 채취한 샘플을 처리하고, 원격의료 플랫폼을 통해 정확한 진단 결과를 원격으로 제공하는 것으로, 임상 검사 서비스 시장 전망은 양호합니다.
The global clinical laboratory services market size was valued at USD 256.9 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 391.8 Billion by 2033, exhibiting a CAGR of 4.80% during 2025-2033. North America currently dominates the market, holding a significant market share of over 39.2% in 2024. The growing demand for diagnostic tests, such as blood glucose tests, HbA1c testing, and lipid profiles to manage diabetes, rising reliance on telehealth to access clinical laboratory services as it can reduce barriers to healthcare and increase overall testing volumes, and the increasing trend of precision medicines are positively fueling the clinical laboratory services market share.
The clinical laboratory services market is driven by several key factors. The rising global burden of chronic and infectious diseases necessitates early and accurate diagnostics, boosting demand for lab testing. Technological advancements, including automation, molecular diagnostics, and AI-based tools, have improved test precision, speed, and efficiency, enhancing overall service delivery. An aging population, more prone to health issues, further drives the need for regular and specialized testing. Increased awareness of preventive healthcare and wellness screenings also contributes to market expansion. Moreover, the growth of personalized medicine and companion diagnostics has increased the demand for advanced laboratory services. Government initiatives, improved healthcare access, and the expansion of health insurance coverage additionally support the growing role of clinical laboratories in modern healthcare.
The clinical laboratory services market growth in the United States is fueled by the rising prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders, which is fueling the demand for diagnostic testing. Advancements in laboratory technologies, including molecular diagnostics and automation, are enhancing test accuracy and turnaround times. An aging population, growing health awareness, and the emphasis on preventive care are further accelerating the need for routine and specialized lab services. Additionally, expanding insurance coverage and government support for early disease detection contribute to market growth. The rise of personalized medicine also drives demand for advanced clinical laboratory testing in the U.S. For instance, in June 2024, the US laboratory services firm Labcorp introduced Labcorp Global Trial Connect, a collection of central laboratory solutions aimed at speeding up clinical trials, especially at investigator locations. The collection of digital and data solutions seeks to improve trial efficiency, minimize data lags, and simplify workflows at investigator sites. It is accessible to current clients of Labcorp Central Laboratory and aims to accelerate the initiation of clinical trials, sustain study progress, and improve trial efficiency.
Clinical Laboratory Services Market Trends
Rising prevalence of diabetes
There is a rise in the demand for diagnostic tests, including HbA1c testing, blood glucose tests, and lipid profiles, to manage diabetes. These tests are also crucial for diagnosing diabetes, monitoring blood sugar levels, and assessing associated cardiovascular risk factors. To effectively manage diabetes, there is a need to monitor blood glucose levels regularly. Clinical laboratories are very essential as they can help in monitoring glycemic control, kidney function, lipid levels, and other biomarkers. For preventing complications, such as diabetic retinopathy, nephropathy, and neuropathy, clinical laboratories perform screening tests. These screening tests allow for timely intervention that can assist in preventing progression of diabetes. People prefer point-of-care testing (POCT) as it allows rapid testing and immediate results. This testing is more successful for monitoring patients with diabetes. As per the data published on the website of IDF Diabetes Atlas, it is projected that around 783 million people will be suffering from diabetes by 2045.
Growing demand for precision medicine
The IMARC Group's report shows that the global precision medicine market reached USD 75.2 Billion in 2023. Genetic testing, genomic sequencing, and molecular diagnostics are important for precision medicines to identify biomarkers, genetic variations, and specific molecular targets. According to the clinical laboratory services market forecast, these tests are performed in clinical laboratories, as they help in predicting disease risks, selecting the most effective therapies as an individual's genetic characteristic, and guiding treatment decisions. To develop and perform companion diagnostics, clinical laboratories are very crucial, which is strengthening the market growth. Companion diagnostics are tests used to identify biomarkers to calculate the success rate of any specific targeted therapy. After knowing this, treatment choices in oncology, infectious diseases, and other therapeutic areas can be optimized. It is very important to analyze genetic variations to monitor the respond of medications in individuals, and pharmacogenomic plays an important role in this analysis. Clinical laboratories provide pharmacogenomic testing to predict drug efficacy, dosage requirements, and potential adverse reactions.
Increasing trend of telehealth
People prefer telehealth nowadays, as it can help connect with doctors even if they are in remote locations. They can also access clinical laboratory services through telehealth platforms, reducing barriers to healthcare and increasing overall testing volumes. It becomes easy to monitor chronic conditions like diabetes remotely through telehealth. Clinical laboratories are very important for the ongoing management of these diseases and improving patient outcomes. Major players operating in the telehealth market are focusing on collaborations and partnerships to expand their customer base. For instance, in 2023, Zoom Video Communications, Inc. and Oracle extended their partnership to provide healthcare services that are quicker, simpler, and more efficient. Home-based kits are distributed by clinical laboratories, and then they process the samples collected at home to provide accurate diagnostic results remotely through telehealth platforms, thereby offering a favorable clinical laboratory services market outlook.
Clinical chemistry stands as the largest test type in 2024, holding 46.7% of the market share. Clinical chemistry can be defined as a broad range of tests that assess the biochemical components of blood, urine, and other bodily fluids. To diagnose and track a variety of medical disorders, these tests are important as they can provide vital information on hormone levels, organ function, electrolyte balance, and metabolic processes. Regular health screenings and follow-up care for patients with chronic diseases also include many clinical chemistry tests. To evaluate general health status and identify problems, tests such as complete metabolic panels (CMP) and basic metabolic panels (BMP) are frequently ordered.
Hospital-based laboratories lead the market with 53.6% of market share in 2024. Hospital-based laboratories are essential components of healthcare facilities as they are closely linked to the whole range of patient services. Within the hospital setting, they provide diagnostic services for surgical units, outpatient clinics, inpatients, and patients in the emergency room. A wide variety of diagnostic tests are usually available at hospital laboratories to support different patient demographics and medical specialties. Clinical chemistry, hematology, immunology, microbiology, molecular diagnostics, and pathology services are all included in this. They offer a one-stop shop for a variety of diagnostic testing requirements.
Bioanalytical and lab chemistry services lead the market with around 38.6% of market share in 2024. Clinical diagnostics and biomedical research depend heavily on a wide range of tests and analyses that are provided by bioanalytical and lab chemistry services. Assays for biomarkers, drug concentrations, metabolites, and other biochemical components in biological samples are among the services provided by these labs. Pharmacokinetic (PK) and pharmacodynamic (PD) investigations are two important steps in the drug development process that bioanalytical services provide for the pharmaceutical and biotechnology industries. Clinical laboratories offer bioanalytical services for measuring drug concentrations in biological matrices, evaluating medication safety and efficacy in clinical trials, and assessing drug metabolism.
In 2024, North America accounted for the largest market share of over 39.2%. North America has highly developed healthcare systems with cutting-edge infrastructure and widespread access to healthcare services, especially in the United States and Canada. This includes a reputable network of clinics, hospitals, and diagnostic labs that provide a wide range of clinical laboratory services. When it comes to healthcare spending worldwide, the US regularly comes in top. The rapid rise of clinical laboratory services can be attributed to the significant investments made in healthcare infrastructure, technology, and services. The market-driving initiatives of illness monitoring, tailored medication, and diagnostic testing are bolstered by healthcare spending. Key players operating in the US are also focusing on providing tests that support novel technology. For instance, in 2023, Dutch biotech firm Detact Diagnostics' announced about its plans to begin bacterial detection sampling at its laboratory in the Keene State College situated in the US.
United States Clinical Laboratory Services Market Analysis
In 2024, the United States accounted for 88.50% of the clinical laboratory market in North America. The United States is experiencing a surge in clinical laboratory services adoption driven by the increasing trend of telehealth. For instance, more than seven billion clinical lab tests are performed in the U.S. each year, providing critical data for a relatively small expenditure. As more patients access remote consultations and digital health platforms, the demand for timely and accurate diagnostic support continues to expand. Clinical laboratories are playing a central role in supporting these virtual health services, offering integrated test processing and dissemination results through electronic health records and patient portals. The seamless coordination between telehealth providers and diagnostic labs enables faster treatment decisions, improving overall patient management. Healthcare providers increasingly rely on these services to enhance chronic disease monitoring, acute illness diagnosis, and preventive care assessments. This shift aligns with broader digital health adoption and reimbursement frameworks, fueling continued investment in clinical laboratory services infrastructure to meet growing national demand.
Asia Pacific Clinical Laboratory Services Market Analysis
Asia-Pacific is witnessing rising clinical laboratory services adoption due to the growing prevalence of diabetes across the region. For instance, according to a 2023 study by the Indian Council of Medical Research-India Diabetes (ICMR INDIAB), 10.1 crore people have diabetes. This chronic condition demands frequent monitoring and diagnostic interventions, including blood glucose analysis, HbA1c testing, and related screenings. The increasing burden of diabetes is placing clinical laboratories at the forefront of disease management strategies, with healthcare systems integrating regular lab diagnostics into outpatient and community care settings. Additionally, growing health awareness and expanding access to medical facilities contribute to higher test volumes. Patients seek regular monitoring for disease progression and treatment response, pushing laboratories to scale operations. Public and private health institutions are actively expanding their diagnostic capabilities to accommodate this trend, positioning clinical laboratory services as a crucial component in controlling the diabetes epidemic across diverse population groups.
Europe Clinical Laboratory Services Market Analysis
Europe is experiencing a rapid rise in clinical laboratory services adoption, attributed to significant investments made in healthcare infrastructure, technology, and services. For instance, France (11.9%), Germany (12.6%), and Austria (11.2%) had the highest current healthcare spending as a percentage of GDP in 2022 among EU nations. Governments and private entities are channeling resources into modernizing diagnostic capabilities, automating laboratory workflows, and enhancing data interoperability across systems. These upgrades facilitate quicker test results, higher testing volumes, and better integration with healthcare delivery networks. Technological advancements, including molecular diagnostics and high-throughput platforms, are being widely implemented, transforming traditional laboratory environments into dynamic hubs for precision medicine. Additionally, healthcare policy reforms are supporting broader access to diagnostic services, encouraging regular screenings and early disease detection.
Latin America Clinical Laboratory Services Market Analysis
Latin America is expanding its clinical laboratory services adoption in response to increasing healthcare facilities and privatization. The National Confederation of Health (CNSaude) and the Brazilian Federation of Hospitals (FBH) report that 62% of Brazil's 7,191 hospitals are private. As private healthcare providers enter the market, investments in diagnostic capabilities grow, leading to a rise in clinical lab testing volumes. Enhanced infrastructure, supported by modern diagnostic tools and expanding hospital networks, is improving access to laboratory services. This growth aligns with rising demand from patients utilizing healthcare facilities more frequently, including those relying on routine and preventive care. The privatization trend is accelerating service quality improvements.
Middle East and Africa Clinical Laboratory Services Market Analysis
The Middle East and Africa are observing greater clinical laboratory services adoption due to rising demand for diagnostic tests such as blood glucose tests, HbA1c testing, and lipid profiles. For instance, the International Diabetes Federation (IDF) reports that the prevalence of diabetes is 9.3% globally and 16.3% in the United Arab Emirates. Growing awareness of chronic diseases and preventive care is prompting individuals to seek early and accurate diagnosis. Health systems across the region are strengthening diagnostic capabilities to meet increasing test volumes. Expanding access to primary care and diagnostic services is positioning clinical laboratories as key players in disease monitoring and treatment support.
Leading clinical laboratory services companies are aggressively pursuing a range of tactics to fortify their positions in the market and satisfy the expanding need for diagnostic tests. Businesses are reaching more patients worldwide and providing a wider choice of tests by partnering with other companies and increasing their service portfolios through acquisitions. For instance, in 2023, Tufts Medicine, a preeminent integrated academic health system in Massachusetts, and Labcorp, a global leader in innovative and comprehensive laboratory services, announced an agreement to purchase the Tufts Medicine outreach laboratory business and certain operating assets as a precursor to a more extensive strategic partnership. Major firms are also making significant investments in cutting-edge technologies including automation, digital pathology, and next-generation sequencing to increase the precision, effectiveness, and turnaround times of their services. By creating and utilizing specific tests for genetic and molecular diagnostics, they are also concentrating on customized medicine, which supports precision medicine and focused therapeutics.